108 related articles for article (PubMed ID: 3087015)
21. Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma.
Alessi MC; Juhan-Vague I; Declerck PJ; Collen D
Thromb Res; 1991 May; 62(4):275-85. PubMed ID: 1907771
[TBL] [Abstract][Full Text] [Related]
22. Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated protein C.
Fay WP; Owen WG
Biochemistry; 1989 Jul; 28(14):5773-8. PubMed ID: 2505842
[TBL] [Abstract][Full Text] [Related]
23. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator.
Hekman CM; Loskutoff DJ
Arch Biochem Biophys; 1988 Apr; 262(1):199-210. PubMed ID: 3128176
[TBL] [Abstract][Full Text] [Related]
24. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1.
Booth NA; Walker E; Maughan R; Bennett B
Blood; 1987 Jun; 69(6):1600-4. PubMed ID: 2953396
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
Booth NA; Simpson AJ; Croll A; Bennett B; MacGregor IR
Br J Haematol; 1988 Nov; 70(3):327-33. PubMed ID: 3264718
[TBL] [Abstract][Full Text] [Related]
27. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.
Lindahl TL; Ohlsson PI; Wiman B
Biochem J; 1990 Jan; 265(1):109-13. PubMed ID: 2105714
[TBL] [Abstract][Full Text] [Related]
28. Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line.
Wagner OF; Vetterlein M; Binder BR
J Biol Chem; 1986 Nov; 261(31):14474-81. PubMed ID: 3490474
[TBL] [Abstract][Full Text] [Related]
29. Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta. Evidence for vitronectin/PAI-2 complexes in human placenta extract.
Radtke KP; Wenz KH; Heimburger N
Biol Chem Hoppe Seyler; 1990 Dec; 371(12):1119-27. PubMed ID: 1708670
[TBL] [Abstract][Full Text] [Related]
30. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.
Wun TC; Palmier MO; Siegel NR; Smith CE
J Biol Chem; 1989 May; 264(14):7862-8. PubMed ID: 2470735
[TBL] [Abstract][Full Text] [Related]
31. Platelet release protein which inhibits plasminogen activators.
Booth NA; Anderson JA; Bennett B
J Clin Pathol; 1985 Jul; 38(7):825-30. PubMed ID: 3926830
[TBL] [Abstract][Full Text] [Related]
32. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.
Kruithof EK; Tran-Thang C; Bachmann F
Thromb Haemost; 1986 Feb; 55(1):65-9. PubMed ID: 3085266
[TBL] [Abstract][Full Text] [Related]
33. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
Lucore CL; Fujii S; Sobel BE
Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
[TBL] [Abstract][Full Text] [Related]
34. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
Estellés A; Gilabert J; Andrés C; España F; Aznar J
Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
36. Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes.
Simon DI; Xu H; Vaughan DE
Biochim Biophys Acta; 1995 Aug; 1268(2):143-51. PubMed ID: 7662701
[TBL] [Abstract][Full Text] [Related]
37. Plasminogen activator inhibitor activity in bacterial infection.
Páramo JA; Fernández Diaz FJ; Rocha E
Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
[TBL] [Abstract][Full Text] [Related]
38. The potential role of platelet PAl-1 in t-PA mediated clot lysis of platelet rich plasma.
Serizawa K; Urano T; Kozima Y; Takada Y; Takada A
Thromb Res; 1993 Aug; 71(4):289-300. PubMed ID: 8236158
[TBL] [Abstract][Full Text] [Related]
39. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
40. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
Leiper K; Croll A; Booth NA; Moore NR; Sinclair T; Bennett B
J Clin Pathol; 1994 Mar; 47(3):214-7. PubMed ID: 8163691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
